Amatuximab (Anti-Mesothelin) is a chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed in many epithelial-derived cancer cells. MW: 145.5 kD.